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After evaluating the prevalence of early endothelial dysfunction, as measured by means of reactive hyperemia in adolescents with
type 1 diabetes, we started a 6-month, double-blind, randomized trial to test the efficacy of an antioxidant diet (± alpha-lipoic acid
supplementation) to improve endothelial dysfunction. Seventy-one children and adolescents, ages 17 ± 3.9 yrs, with type 1 diabetes
since 9.5 ± 5.3 yrs, using intensified insulin therapy, were randomized into 3 arms: (a) antioxidant diet 10.000 ORAC + alpha-
lipoic acid; (b) antioxidant diet 10.000 ORAC + placebo; (c) controls. BMI, blood pressure, fasting lipid profile, HbA1c, insulin
requirement, dietary habits, and body composition were determined in each patient. An antioxidant diet significantly improved
endothelial dysfunction when supplemented with alpha-lipoic acid, unlike diet with placebo or controls. A significant reduction in
bolus insulin was also observed. We speculate that alpha-lipoic acid might have an antioxidant effect in pediatric diabetes patients
by reducing insulin.
1. Introduction
Atherosclerosis and its vascular damage are the leading cause
ofmortality andmorbidity in patientswith diabetes. Recently,
several studies have shown that cardiovascular diseases are
the first cause of premature death among individuals with
type 1 diabetes, demonstrating that although there have been
substantial improvements in survival during the past 50 years,
still challenges remain [1].
Although diabetes-related vascular complications are
uncommon in the pediatric age, early functional and struc-
tural abnormalities may be present just a few years after
the onset of type 1 diabetes [2]. Therefore, early diagnostic
and therapeutic approaches are needed for youth with type
1 diabetes at risk for a premature vascular disease.
A surrogate marker of cardiovascular disease is endothe-
lial dysfunction [3], which is the inability of the artery to suffi-
ciently dilate in response to an appropriate endothelial stimu-
lus.The reactive hyperemia peripheral artery tonometry tech-
nique is used for a few years now as a noninvasive test to assess
for early vascular changes in high-risk patient groups [4].
In a previous study [5], we evaluated the prevalence
of endothelial dysfunction measured as mean of reactive
hyperemia index (RHI), in a cohort of adolescents with type
1 diabetes. Surprisingly a low RHI score was observed in
76.7% of patients, showing a dramatic prevalence of early
endothelial dysfunction among type 1 diabetes individuals,
even in the pediatric age [5].
Endothelial cells have got numerous functions crucial
for maintaining intravascular homeostasis: they play an
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important role in vascular tone regulation, hemostasis, and
fibrinolysis and in the production of several substances [6,
7]. In patients with diabetes, hyperglycemia and related
pathological biochemical processes trigger damage to the
endothelial cells causing their dysfunction.The dysfunctional
endothelium adopts prothrombotic, proinflammatory, and
vasoconstrictive phenotype promoting the early development
of atherosclerosis [3, 6, 7].
Alpha-lipoic acid is a potent mitochondrial antioxidant
agent that acts by multiple mechanisms promoting anti-
inflammatory and antithrombotic pathways and positively
influencing the nitric oxide mediated vasodilatation [8].
In most European countries alpha-lipoic acid is licensed
and used as treatment in patients with neuropathic symptoms
[9]. Moreover, many studies suggest the potential role of
alpha-lipoic acid in prevention and treatment of atheroscle-
rosis and related cardiovascular disease [10, 11].
The hypothesis is that alpha-lipoic acid may improve
the endothelial function.This hypothesis is based on similar
results obtained either in animal models or in patients
with diabetes mellitus, especially type 2 diabetes [12–14]. In
streptozotocin-induced rats, it may be assumed that alpha-
lipoic acid treatment can protect against impaired vascular
responsiveness [12]. In type 2 diabetes patients, alpha-lipoic
acid may influence angiogenesis through an effect on some
circulating factors including VEGF, bFGF, MCP-1, and IL-10
[14].
Therefore, the aim of our study was to investigate the
effect of alpha-lipoic acid on endothelial dysfunction in youth
with type 1 diabetes. This pilot study is a 6-month, double-
blind, randomized controlled trial to test the efficacy of an
antioxidant diet plus alpha-lipoic acid versus an antioxidant
diet alone in improving endothelial dysfunction in adoles-
cents with type 1 diabetes.
2. Methods
2.1. Study Design. This study was a 6-month, prospective,
randomized, double-blind, controlled trial conducted in
pediatric patients with type 1 diabetes, performed at the
Pediatric Department of the University of Milano. The trial
was reviewed and approved by the “Luigi Sacco” Hospital
Ethics Committee.
The trial was performed in accordance with the Decla-
ration of Helsinki. Before any trial-related activities signed
informed consent was obtained from all participants aged 16
years or older and from parents or guardians of participants
aged younger than 16 years (assent was obtained from
minors).
2.2. Participants and Study Procedures. Patients with type
1 diabetes were referred for study participation from the
outpatient clinic of the University of Milano between January
2013 and December 2013. Seventy-one patients who had
been previously evaluated for the presence of endothelial
dysfunction [5] were enrolled in the trial and completed the
6-month study period.
Inclusion criteria were type 1 diabetes (diabetes onset
was defined according to ADA criteria), more than 1 year
fromdiagnosis or confirmedC-peptide negative, age between
12 and 19 years, insulin requirement more than or equal to
0.5U/kg/day, blood glucose checks more the 3 times per
day, and insulin intensive therapy ongoing. Exclusion criteria
were preexisting cardiovascular diseases or inflammatory
systemic diseases, hypertension and prehypertension (BP ≥
90th percentile for age, sex, and height), eating disorders,
obesity (defined as BMI ≥ 95th percentile per age and sex
in the 2000 CDC growth chart), celiac disease, inflammatory
bowel disease or other significant gastrointestinal condi-
tions, systemic glucocorticoid use (1-month cumulative use
during last year) or ongoing treatment with glucocorticoid
use, anemia, significant multiple food allergies, uncontrolled
hypothyroidism or hyperthyroidism, significant mental ill-
ness, and pregnancy.
2.3. Measurements. Clinical history and physical exami-
nation, nutritional records, and biochemical sample were
collected at baseline, after 3 months, and after 6 months;
endothelial dysfunction was evaluated at baseline and after
6months.
2.4. Clinical Parameters. Height was measured to the nearest
centimeter using a rigid stadiometer. Weight was measured
unclothed to the nearest 0.1 kg using a calibrated balance
scale. Body mass index (BMI) was calculated for each
patient. The pubertal developmental stage was determined
according to Marshall and Tanner scale. Blood pressure was
measured using a mercury sphygmomanometer, according
to the National High Blood Pressure Education Program
Working Group. Moreover, 24 h blood pressure was recorded
in all patients.
All patients were in intensive insulin therapy, with either
multiple daily injections or insulin pump therapy. Daily
insulin requirement was calculated as total dose and as basal
and bolus rates.
2.5. Biochemical Parameters. Blood sampling was performed
in the fasting state at 8 a.m. Levels of lipids including
triglycerides (TG), total cholesterol (TC), LDL-cholesterol,
and HDL-cholesterol were evaluated in all subjects with
standard laboratory methods.
Blood was drawn for HbA1c analysis using a fully
automated high-performance liquid chromatography system
(Variant II, Bio-Rad Laboratories, Munich, Germany).
2.6. Nutritional Assessment. At baseline and 3 and 6 months
a nutritional visit was performed by the registered dietitian
of the Pediatric Department of the “Luigi Sacco” Hospital.
Three-day dietary records with nutrition data were evaluated
using dedicated software (Metadieta,MeTeDa, San Benedetto
del Tronto, AP, Italy). Data on dietary intake, reporting the
types and amounts of all food and beverages consumed, with
data on insulin doses and algorithms used at home, blood
glucose results, and physical activity were collected. During
the study period a dietary recall was collected every month;
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moreover a nutritional assessment was performed at 3 and 6
months to check the patients’ compliance to the dietary plan
assigned.
Moreover, registered dietitian evaluated the body compo-
sition using Tanita BC-418, IL, USA.
2.7. Endothelial Dysfunction. Peripheral endothelium-
dependent vasodilator capacity was estimated by assessing
the RHI by means of the EndoPAT 2000 system (Itamar
Medical Ltd., Caesarea, Israel) [5]. Endothelium-mediated
changes in vascular tone after occlusion of the brachial
artery are reflecting a downstream hyperemic response,
which is a measure for arterial endothelial function. The
RH-PAT score is calculated as the ratio of the average pulse
wave amplitude during 1min period starting 60 s after cuff
deflation divided by the average pulse wave amplitude of a
210 s preocclusion baseline period. Lower RH-PAT scores
reflect more pronounced endothelial dysfunction.
2.8. Randomization. After the clinical assessment at baseline,
each patient was randomly assigned to one of the three
double-blind, study arms: 10.000 oxygen radical absorbance
capacity units (ORAC) antioxidant diet plus alpha-lipoic acid
(푛 = 25, group 1), 10.000 ORAC antioxidant diet plus
placebo (푛 = 27, group 2), and controls (푛 = 19, group
3), with no changes in dietary habits. A computer-generated
randomization list assigned participants to each group.
Supplementation with 400mg of slow-release alpha-
lipoic acid or placebo, both in a lyophilized formulation, was
furnished by the RA of the Pediatric Department. Patients
were advised to melt the lyophilized solution in a glass of
water and to get it twice a day at least 1 hour before lunch and
dinner, for 6 months. The compliance with the antioxidant
diet was monitored by monthly dietary recalls and a full
nutritional assessment was repeated, after 3 and 6months.
Both patients treated with antioxidant diet plus alpha-
lipoic acid (푛 = 25, group 1) and patients treated with
antioxidant diet plus placebo (푛 = 27, group 2) received the
same diet plan, of 1800–2200Kcal per day, according to the
age-group.The daily amount of carbohydrates was 60%of the
total intake, with 15%of simple carbohydrates.The prescribed
amount of fiber was 40 gr per day; fats were 26%, with a
monosaturated percentage of 12, polysaturated percentage of
4, and saturated percentage of 8. The ratio of the fatty acid
was 8 gr for omega-6 and 2 gr for omega-3.The daily amount
of proteins was 14% of the total intake, with 54% of animal
proteins and 46% of vegetable proteins. Moreover at least
10.000 ORAC as foods were prescribed in the dietary plan.
No particular nutrient source to elevate the dietary ORAC
was administered, but a list of foods with high ORAC content
was given to each subject with detailed instruction to reach
the desired assumption of ORAC.
A similar dietary plan was assigned to patients enrolled
in the control group (푛 = 19, group 3), but no ORAC sup-
plementation was suggested.
2.9. Statistics. Prior to data analysis, all metric variables were
checked for normality by using Shapiro-Wilk test. Data were
normally distributed.We used unpaired 푡-test andMANOVA
(multiple analysis of variance) when appropriate. Results are
presented as mean ± standard deviation (SD), or percentage,
unless stated otherwise. All 푝 values less than 0.05 were
considered statistically significant. Statistical analyses were
performed using IBM SPSS Statistics package version 20.
3. Results
All the 71 patients enrolled completed the 6-month study
period and no one dropped out of study before completing
it. Moreover no severe side effects have been reported by
either alpha-lipoic acid group or placebo. Either severe
hypoglycemic events or DKA episodes occurred during the
6-month study.Three patients of the alpha-lipoic acid group
and 2 patients of the control group reported mild abdominal
pain over the first 4 weeks of the study, with no need to
withdraw from the study.
Baseline and 6-month clinical characteristics are summa-
rized in Table 1 for each study group. At baseline, the mean
age of the whole group was 16.3 ± 3.4 years, the mean of
diabetes duration was 8.1 ± 5.2 years, the mean BMI was
21 ± 3, and insulin requirement was 0.83 ± 0.29U/kg/day.
The mean value of HbA1c (%) was 7.96 ± 1.04 at baseline.
All patients enrolled in the study reported in-range levels
of triglycerides, total cholesterol, LDL-cholesterol, and HDL-
cholesterol per age and sex over the study period. Moreover
all patients showed normal blood pressuremeasurements per
age, sex, and height. There was no statistical difference in
all the demographic and clinical variables considered among
the three study groups at baseline (Table 1). After 3 months,
a significant reduction in daily insulin requirements was
observed only in group 1, both in the amount of the total
daily dose (0.74U/kg/day at 3 months versus 0.83U/kg/day
at baseline, 푝 = 0.048) and in the percentage of bolus (22.0%
at 3 months versus 26.3% at baseline, 푝 = 0.047) (Table 1).
However these data were not confirmed at 6months, and no
differences were reported among the 3 groups after 6months
of diet in terms of daily insulin requirement.
These results are supported by data collected during
the nutritional assessment. Indeed, dietary recall to evaluate
patients’ compliance to the dietary plan showed a significant
increase of ORAC intake at month 3 in both arms (treatment
and placebo) but not in controls. After 6 months, ORAC
consumption decreased in the treatment group but not in the
placebo group, as reported in Table 1.
Endothelial dysfunction was tested as RHI score in all
groups at baseline and after 6months.
As described in a previous study [5], at baseline a lowRHI
score was reported in all patients enrolled, which resulted
in a pathologic range (<1.67). At 6 months, RHI score
significantly improved only in the group of patients treated
with antioxidant diet plus alpha-lipoic acid (1.72 versus 1.4,푝 = 0.045), reaching a normal RHI value [5] (Table 1 and
Figure 1).The group of patients treated with antioxidant diet
plus placebo reported a better RHI score at 6 months versus
baseline as well, but it did not reach the significance. No
differences in RHI score were showed in the control group
at 6months versus baseline.
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Table 1: Clinical characteristics of the three study groups at baseline and after 3 and 6months of follow-up.
Group 1
(푛 = 25) Group 2(푛 = 27) Group 3(푛 = 19) All(푛 = 71) 푝∗
Sex (M/F) 15/10 16/11 11/8 42/29 0.699
Age (years) 16.1 ± 3.1 16.0 ± 3.4 16.5 ± 4.3 16.3 ± 3.4 0.916
Diabetes duration (years) 7.7 ± 4.9 8.2 ± 5.6 8.8 ± 5.7 8.1 ± 5.2 0.743
BMI (kg/m2) 21 ± 2 22 ± 3 21 ± 3 21 ± 3 0.911
Insulin requirement (U/kg/day) 0.83 ± 0.26 0.85 ± 0.31 0.77 ± 0.33 0.83 ± 0.29 0.775
Insulin requirement (U/kg/day)
after 3months
0.74 ± 0.18
0.049 versus baseline 0.86 ± 0.27 0.86 ± 0.19 0.82 ± 0.21 0.211
Insulin requirement (U/kg/day)
after 6months
0.85 ± 0.30
0.007 versus 3mo 0.83 ± 0.29 0.89 ± 0.19 0.86 ± 0.26 0.887
Basal dose (U/day - %) 25.5 ± 8.6(50 ± 11) 25.4 ± 7.6(51 ± 9) 28.4 ± 12.2(50 ± 11) 26.4 ± 9.5(50 ± 10) 0.7330.789
Basal dose (U/day - %)
after 3months
25.9 ± 9.4
(53 ± 12) 25.4 ± 8.0(51 ± 7) 29.4 ± 10.7(52 ± 8) 27.0 ± 9.4(52 ± 9) 0.5130.563
Basal dose (U/day - %)
after 6months
25.8 ± 9.4
(52 ± 14) 25.6 ± 8.3(52 ± 9) 29.6 ± 11.3(52 ± 9) 27.2 ± 9.7(59 ± 10) 0.5130.996
Bolus dose (U/day - %) 26.3 ± 10.8(50 ± 12) 25.6 ± 13.2(51 ± 9) 24.4 ± 9.0(47 ± 7) 25.4 ± 11.0(49 ± 9) 0.9160.739
Bolus dose (U/day - %)
after 3months
22.0 ± 9.4
(47 ± 12)
0.047 versus baseline
25.8 ± 11.9
(49 ± 7) 25.9 ± 6.4(48 ± 8) 24.6 ± 9.2(48 ± 9) 0.4010.564
Bolus dose (U/day - %)
after 6months
25.9 ± 13.3
(48 ± 14) 24.1 ± 12.4(47 ± 9) 25.9 ± 6.1(48 ± 9) 25.3 ± 10.6(48 ± 11) 0.8640.989
HbA1c (%) 7.97 ± 1.19 7.96 ± 1.04 7.91 ± 0.76 7.96 ± 1.04 0.856
Reactive hyperemia index 1.40 ± 0.68 1.39 ± 0.41 1.58 ± 0.64 1.47 ± 0.59 0.349
Reactive hyperemia index
after 6months
1.72 ± 0.66
0.045 versus baseline 1.58 ± 0.40 1.54 ± 0.42 1.62 ± 0.51 0.002
ORAC in the diet 8872,43 ± 5378,22 9771,96 ± 6266,26 9503,25 ± 9973,67 9382,55 ± 7206,05 0.638
ORAC in the diet at 3months 11844,09 ± 5603,01 12874,04 ± 7165,52 8489,71 ± 6946,57 11069,28 ± 6571,53 0.036
ORAC in the diet at 6months 12518,70 ± 5908,64 15496,83 ± 6897,98 11306,83 ± 11737,31 13107,45 ± 8181,31 0.098∗By MANOVA test.
BMI = body mass index; HbA1c = glycosylated hemoglobin; ORAC = oxygen radical absorbance capacity.
0 0.5 1 1.5 2 2.5
ORAC +
a-lipoic acid
ORAC +
placebo
Controls
RH-PAT score
p = 0.045 versus baseline
Figure 1: Endothelial function as RH-PAT score at baseline (◼) and
after 6-month follow-up (◻); dotted line represents the normal value
for the test.
The analyses performed on the other clinical parameters
collected showed no differences at baseline and after 3 and 6
months among the three groups: BMI, 24 h blood pressure,
lipid profile, HbA1c, dietary habits, and body composition
resulted any different among the three groups and over the
study period.
4. Discussion and Conclusion
To the best of our knowledge, this is the first study analyzing
the effects of a dietary supplementation in improving the
endothelial dysfunction in youth with type 1 diabetes.
In this randomized, placebo controlled double-blind trial,
we found a relationship between the consumption of an
antioxidant diet plus alpha-lipoic acid and the improvement
in endothelial dysfunction in youth with type 1 diabetes.
In particular an antioxidant diet (10000 ORAC) plus alpha-
lipoic acid (800mg/day) seems to be effective in reducing
insulin requirement and daily bolus rate after 3 months and
in improving endothelial dysfunction after 6months.
The efficacy of alpha-lipoic acid in improving glucose
disposal has been previously described in animal models
[12–15] and in type 2 diabetes adult patients [13, 14, 16]. It
was 1970 when lipoic acid was shown to enhance glucose
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uptake into rat tissue [17, 18]. Gradually the effects of different
formulas of alpha-lipoic acid were tested both in vitro and
in animal models [16, 19] confirming the ability to increase
glucose uptake and to enhance the glycogen synthesis [16, 19].
The molecule seems to work improving insulin sensitivity
by modulating the signal transduction and by increasing the
glucose uptake. In patients with type 2 diabetes, an acute
intravenous administration of 1000mg of lipoic acid was
reported to significantly improve insulin-stimulated glucose
disposal [20]. Moreover a 4-week oral treatment with alpha-
lipoic acid successfully resulted in increasing insulin sensitiv-
ity in patients with type 2 diabetes [21].
In our small study, a supplementation with 800mg/day
of alpha-lipoic acid for 3 months effectively resulted in
reducing insulin requirement. The mechanisms of action
are not completely clear, since, in our knowledge, studies
having pediatric type 1 diabetes patients as target are lacking.
However, as reported for type 2 diabetes, we hypothesize that
alpha-lipoic acid can use nicotinamide adenine dinucleotide
molecules (NADH) for the reduction to dihydrolipoic acid,
resulting in an increased ratio of nicotinamide adenine
dinucleotide (NAD+) to NADH and thus stimulating the
glycolysis pathway [22].
In our study the alpha-lipoic beneficial effect on insulin
requirement and thus on glucose uptake is reported at 3
months but it is not confirmed at 6 months. In our opinion
this can be explained by a decreased compliance to the dietary
supplementation, as confirmed by dietary recall and by data
collected during the nutritional assessments.
We also demonstrated for the very first time the power
of alpha-lipoic acid in improving endothelial dysfunction in
youths with type 1 diabetes. In our cohort of patients, the
prevalence of endothelial dysfunction is largely represented,
despite the pediatric age and the quite goodmetabolic control
[5]. Data from registries has recently shown that a large
proportion of the type 1 diabetic population does notmeet the
age-associated HbA1c targets across all countries, especially
in the youth age [23]. Moreover, data recently published by
Lind and colleagues [24] showed that patients with type 1
diabetes and on-target HbA1c still have a risk of death from
any cause and from cardiovascular diseases more than twice
the risks in the general population. These dramatic data ask
for new insights into the pathogenesis of diabetes-related
complications, as well as for new therapeutic approaches.
Thus, during the last decades, many studies have been
conducted to investigate the role of inflammation in diabetes
onset and in diabetes-related complications.The opportunity
for an early detection of endothelial dysfunction can lead to
new insights into the very first steps of the cardiovascular
complications. Indeed, endothelial cells play a wide spectrum
of different functions, as regulating coagulation, leukocyte
adhesion, and trafficking, modifying the tone of the vessel,
and participating in the smooth-muscle growth [22]. As a
consequence, many different pathways can be affected by
pathologic factors, leading to endothelial dysfunction. Sev-
eral mechanisms have been suggested to explain endothelial
dysfunction: hyperglycemia itself [25], increased oxidative
stress and subsequent AGEs production and protein kinase C
and polyol-pathway activation [26], lower vitamin C plasma
concentration, and significantly higher circulating reactive
protein C levels [27, 28].
Alpha-lipoic acid is reported to be effective in most
of these reactions, getting the role of antioxidant, anti-
inflammatory molecule. Indeed, although it is well defined as
a therapy for preventing diabetic polyneuropathies and it is
used in the management of diabetic peripheral neuropathy
in both patients with type 1 and type 2 diabetes, alpha-
lipoic acid has many biochemical functions. It acts as metal
chelator, as scavenger of free radicals, and as reducer of the
oxidized forms of other antioxidant agents such as vitamins
C and E and it regulates several signal transductions [14]. In
particular alpha-lipoic acid was shown to increase the activity
of eNOS, to downregulate the expression of the cell-adhesion
molecules ICAM-1 and VCAM-1 and of MMP-9 by the inhi-
bition of AGE-induced NF-kB (nuclear factor kappa-light-
chain-enhancer of activated B cells) adhesion factors [14, 22].
Supported by this evidence, we can speculate that a 6-
month supplementation with alpha-lipoic acid 800mg/day
can positively impact endothelial dysfunction, decreasing
oxidative stress and inflammation in type 1 diabetes, even in
pediatrics.
Despite this, these data must be carefully weighed against
the lack of consensus regarding the most appropriate sup-
plementation method for alpha-lipoic acid, dosage, and
treatment duration.
However, in a paper recently published a 3-month treat-
ment with 600mg of alpha-lipoic acid was demonstrated to
provide significant beneficial changes in VEGF, bFGF, MCO-
1, and IL-10 serum levels in type 2 diabetic patients, con-
firming the efficacy of low-period treatment on endothelial
outcomes [29]. Moreover, several studies demonstrated the
efficacy of 600 or more mg of alpha-lipoic acid administered
for few weeks or months [30, 31] in the treatment of diabetic
polyneuropathy.
The strength of our study is the evidence for the first
time of a positive association between alpha-lipoic admin-
istration and decreased endothelial dysfunction in pediatric
patients with type 1 diabetes. Nevertheless the trial has some
limitations, and we strongly advise a larger sample and a
long-term follow-up to confirm these results. Moreover, the
effects of alpha-lipoic acid on glycemic control need to be
investigated as well, both as glycemic variability and hypo-
and hyperglycemic events.
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